- Home
- DOMH vs ACET Comparison
DOMH vs ACET Comparison
Compare DOMH & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- ACET
- Stock Information
- Founded
- DOMH 1967
- ACET 1947
- Country
- DOMH United States
- ACET United States
- Employees
- DOMH N/A
- ACET N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- ACET Health Care
- Exchange
- DOMH Nasdaq
- ACET Nasdaq
- Market Cap
- DOMH 48.5M
- ACET 44.4M
- IPO Year
- DOMH N/A
- ACET N/A
- Fundamental
- Price
- DOMH $4.60
- ACET $0.61
- Analyst Decision
- DOMH
- ACET Buy
- Analyst Count
- DOMH 0
- ACET 6
- Target Price
- DOMH N/A
- ACET $6.00
- AVG Volume (30 Days)
- DOMH 639.5K
- ACET 516.6K
- Earning Date
- DOMH 04-15-2025
- ACET 05-13-2025
- Dividend Yield
- DOMH 6.96%
- ACET N/A
- EPS Growth
- DOMH N/A
- ACET N/A
- EPS
- DOMH N/A
- ACET N/A
- Revenue
- DOMH $18,146,000.00
- ACET N/A
- Revenue This Year
- DOMH N/A
- ACET N/A
- Revenue Next Year
- DOMH N/A
- ACET N/A
- P/E Ratio
- DOMH N/A
- ACET N/A
- Revenue Growth
- DOMH 789.95
- ACET N/A
- 52 Week Low
- DOMH $0.83
- ACET $0.45
- 52 Week High
- DOMH $13.58
- ACET $2.08
- Technical
- Relative Strength Index (RSI)
- DOMH 52.92
- ACET 45.10
- Support Level
- DOMH $3.70
- ACET $0.51
- Resistance Level
- DOMH $4.78
- ACET $0.62
- Average True Range (ATR)
- DOMH 0.42
- ACET 0.06
- MACD
- DOMH 0.17
- ACET 0.01
- Stochastic Oscillator
- DOMH 89.71
- ACET 63.16
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.